New serum markers of hepatocellular carcinoma

Seminars in Oncology

Volumn 39, Issue 4, 2012, Pages 434-439

  Masuzaki, Ryota ^a   Karp, Seth J ^a   Omata, Masao ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b Yamanashi Prefectural Central Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; GLYPICAN 3; OSTEOPONTIN; SCATTER FACTOR; SOMATOMEDIN C; SORAFENIB; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT; CONFERENCE PAPER; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EARLY DIAGNOSIS; ECHOGRAPHY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LENTIL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; OSTEOPONTIN; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864438094     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.05.009     Document Type: Conference Paper

References (58)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2918 2927
2. K. Okuda Hepatocellular carcinoma: recent progress Hepatology 15 1992 948 963
3. S. Sherlock Viruses and hepatocellular carcinoma Gut 35 1994 828 832
4. M. Omata, M. Ashcavai, C.T. Liew, R.L. Peters Hepatocellular carcinoma in the U.S.A., etiologic considerations Localization of hepatitis B antigens Gastroenterology 76 1979 279 287
5. K. Taketa Alpha-fetoprotein: reevaluation in hepatology Hepatology 12 1990 1420 1432
6. T. Sato, R. Tateishi, H. Yoshida Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C Hepatol Int 3 2009 544 550
7. B.J. McMahon, L. Bulkow, A. Harpster Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study Hepatology 32 2000 842 846
8. T. Shinagawa, M. Ohto, K. Kimura Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography A study in 51 patients Gastroenterology 86 1984 495 502
9. K. Takayasu, N. Moriyama, Y. Muramatsu The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients AJR Am J Roentgenol 155 1990 49 54
10. E. Goto, R. Masuzaki, R. Tateishi Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma J Gastroenterol 47 2012 477 485
11. K. Taketa, C. Sekiya, M. Namiki Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions Gastroenterology 99 1990 508 518
12. L. van Staden, S. Bukofzer, M.C. Kew, N. Savage Differential lectin reactivities of alpha-fetoprotein in hepatocellular carcinoma: diagnostic value when serum alpha-fetoprotein levels are slightly raised J Gastroenterol Hepatol 7 1992 260 265
13. F. Yamashita, M. Tanaka, S. Satomura, K. Tanikawa Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas Gastroenterology 111 1996 996 1001
14. R. Tateishi, S. Shiina, H. Yoshida Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers Hepatology 44 2006 1518 1527
15. H. Toyoda, T. Kumada, T. Tada Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL Cancer Sci 102 2011 1025 1031
16. Y. Aoyagi, M. Oguro, M. Yanagi Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma Cancer 77 1996 1781 1786
17. J.A. Marrero, G.L. Su, W. Wei Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients Hepatology 37 2003 1114 1121
18. J. Ikoma, M. Kaito, T. Ishihara Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study Hepatogastroenterology 49 2002 235 238
19. H. Toyoda, T. Kumada, Y. Osaki, T. Tada, Y. Kaneoka, A. Maeda A novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report Cancer Sci 103 2012 921 925
20. K. Hamamura, Y. Shiratori, S. Shiina Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein Cancer 88 2000 1557 1564
21. Y. Koike, Y. Shiratori, S. Sato Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients Cancer 91 2001 561 569
22. K. Murata, H. Suzuki, H. Okano, T. Oyamada, Y. Yasuda, A. Sakamoto Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma Int J Oncol 36 2010 161 170
23. K. Ueshima, M. Kudo, M. Takita Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma Dig Dis 29 2011 321 325
24. M. Ishii, H. Gama, N. Chida Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma South Tohoku District Study Group Am J Gastroenterol 95 2000 1036 1040
25. I.C. Weitz, H.A. Liebman Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review Hepatology 18 1993 990 997
26. S. Fujiyama, M. Tanaka, S. Maeda, H. Ashihara, R. Hirata, K. Tomita Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma Oncology 62 Suppl 1 2002 57 63
27. B.I. Carr, F. Kanke, M. Wise, S. Satomura Clinical evaluation of Lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States Dig Dis Sci 52 2007 776 782
28. K. Izuno, S. Fujiyama, K. Yamasaki, M. Sato, T. Sato Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study Hepatogastroenterology 42 1995 387 393
29. M. Shimada, K. Takenaka, Y. Fujiwara Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma Cancer 78 1996 2094 2100
30. R. Tateishi, H. Yoshida, Y. Matsuyama, N. Mine, Y. Kondo, M. Omata Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review Hepatol Int 2 2008 17 30
31. M.S. Pepe, R. Etzioni, Z. Feng Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 2001 1054 1061
32. Y. Midorikawa, S. Ishikawa, H. Iwanari Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling Int J Cancer 103 2003 455 465
33. Z.W. Zhu, H. Friess, L. Wang Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 2001 558 564
34. M. Capurro, I.R. Wanless, M. Sherman, G. Deboer, W. Shi, E. Miyoshi, J. Filmus Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97
35. Y. Hippo, K. Watanabe, A. Watanabe Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma Cancer res 64 2004 2418 2423
36. T. Nakatsura, Y. Yoshitake, S. Senju Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker Biochem Biophys Res Commun 306 2003 16 25
37. T. Nakamura Structure and function of hepatocyte growth factor Prog Growth Factor Res 3 1991 67 85
38. G. Shiota, J. Okano, H. Kawasaki, T. Kawamoto, T. Nakamura Serum hepatocyte growth factor levels in liver diseases: clinical implications Hepatology 21 1995 106 112
39. T. Tomiya, S. Nagoshi, K. Fujiwara Significance of serum human hepatocyte growth factor levels in patients with hepatic failure Hepatology 15 1992 1 4
40. H. Yamagamim, M. Moriyama, H. Matsumura Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases Cancer 95 2002 824 834
41. R. Baserga The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55 1995 249 252
42. R. Baserga, A. Hongo, M. Rubini, M. Prisco, B. Valentinis The IGF-I receptor in cell growth, transformation and apoptosis Biochim Biophys Acta 1332 1997 F105 F126
43. G. Mazziotti, F. Sorvillo, F. Morisco Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study Cancer 95 2002 2539 2545
44. P.H. Anborgh, J.C. Mutrie, A.B. Tuck, A.F. Chambers Role of the metastasis-promoting protein osteopontin in the tumour microenvironment J Cell Mol Med 14 2010 2037 2044
45. Q.H. Ye, L.X. Qin, M. Forgues Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med 9 2003 416 423
46. H. Zhang, Q.H. Ye, N. Ren The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma J Cancer Res Clin Oncol 132 2006 709 717
47. H.W. Pan, Y.H. Ou, S.Y. Peng Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma Cancer 98 2003 119 127
48. S. Shang, A. Plymoth, S. Ge Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology 55 2012 483 490
49. W.S. Moon, K.H. Rhyu, M.J. Kang Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16 2003 552 557
50. R.T. Poon, J.W. Ho, C.S. Tong, C. Lau, I.O. Ng, S.T. Fan Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma Br J Surg 91 2004 1354 1360
51. A.O. Kaseb, J.S. Morris, M.M. Hassan Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma J Clin Oncol 29 2011 3892 3899
52. J.M. Llovet, S. Ricci, V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
53. A.L. Cheng, Y.K. Kang, Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
54. A.X. Zhu, D.V. Sahani, D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
55. A.X. Zhu, D.G. Duda, M. Ancukiewicz Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value Clin Cancer Res 17 2011 918 927
56. A.X. Zhu, D.G. Duda, D.V. Sahani, R.K. Jain HCC and angiogenesis: possible targets and future directions Nat Rev 8 2011 292 301
57. R. Tateishi, M. Omata Hepatocellular carcinoma in 2011: genomics in hepatocellular carcinoma-a big step forward Nat Rev 9 2012 69 70
58. Y. Totoki, K. Tatsuno, S. Yamamoto High-resolution characterization of a hepatocellular carcinoma genome Nat Genet 43 2011 464 469